Navigation Links
Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
Date:12/3/2007

- Screening Determines Efficacy and Safety of Combination Drug Therapies -

HOPKINTON, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today launched drug combination services through Caliper Discovery Alliances & Services (CDAS). These new services will help researchers determine the efficacy of combination drug therapies and identify potentially harmful combinations before therapies enter clinical trials. Studies, performed in Caliper's anti-cancer cell proliferation panel, cellular cytokine/chemokine release assays or using in vivo efficacy models, will help identify synergistic responses of drug combinations and eliminate antagonistic mixtures of drugs.

Drug combination studies are increasingly valuable to pre-clinical pharmaceutical research. The simultaneous use of a variety of drugs is common today for the treatment of bacterial infections, HIV, hypertension and cancer. Drug combination testing is subsequently a growing trend in many areas including oncology. If a combination is synergistic, lower doses can be used to achieve the same or better efficacy, which can lead to lower toxicity and safer patient care.

"Drug combination studies using cancer cell lines create a relationship between in vitro screening and profiling, and in vivo animal models. This connection is critical as researchers strive to understand how drug combinations may react in humans," said Kevin Hrusovsky, President and CEO, Caliper Life Sciences. "The exact same cell lines used in the in vitro drug combination testing can be used to create in vivo tumor models to further assess efficacy using the IVIS imaging platform."

The CDAS drug combination studies combine the liquid-handling,
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("HMP"), its drug R&D subsidiary, successfully achieved the ... of fruquintinib in patients with advanced non-squamous non-small ... .  The top-line results demonstrated that the ... endpoint of progression free survival ("PFS"). ...
(Date:9/3/2015)... With a population of more than 1 ... also its single largest potential market for goods and ... all major world economies in the average rate of ... health expenditures. As an in vitro diagnostics (IVD) market, ... United States, western European countries, and Japan. China represents ...
(Date:9/3/2015)... NEW YORK , Sept. 3, 2015 ... successfully used to save millions of lives across globe. ... the Kingdom of Saudi Arabia . ... raw material suppliers, government agencies and regulatory bodies. The ... been studied from two perspectives: by products and by ...
Breaking Medicine Technology:Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13Saudi Arabia Defibrillators Market: & Advanced Life Support Defibrillators; End Users; Industry Analysis, Size, Volume, Growth, Trends and Forecast 2014 - 2020 2
... 15, 2012 For the 35 million people ... new, fast, effective approach to treatment is now ... light, radiofrequency and ultrasound aesthetic and medical devices, ... newest innovation for the Harmony(XL) multi-application, multi-technology platform, ...
... BARCELONA, Spain, March 15, 2012 Grifols (MCE:GRF, MCE:GRF.P ... largest plasma product manufacturer and a pioneer in the ... to both scientific and social development, has acquired 51% ... the viability of its projects and the future of ...
Cached Medicine Technology:New Nail Fungus Approach Receives FDA Clearance 2Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 2Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 3Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 4Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 5Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 6Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 7Grifols has Acquired 51% of the Capital of Araclon Biotech to Ensure the Viability of the Purchased Company Projects 8
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law ... De La Paz. , Schmidt National Law Group, a leading firm in mass-tort ... California against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged ...
(Date:9/4/2015)... ... September 04, 2015 , ... After wearing the same uniforms for six ... apparel. In an effort to assist the team, the Jones Agency, a locally owned ... to raise funds for the new uniforms. , As is so often the case ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Keeping mold ... and around the home is quite common. Mold can grow anywhere - on carpet, ... leaking pipes. Checking for excessive moisture and water in the home is key to ...
(Date:9/4/2015)... ... 04, 2015 , ... Many consumers are looking for a quick and convenient way to produce ... patent-pending K Med Cups provide a quick and simple way to brew a hot cup ... or cough. As a result, they enhance comfort and health. The invention features a novel ...
(Date:9/4/2015)... ... ... Having access to a doctor can sometimes be a challenge for a variety ... visits which affects hospitals’ abilities to provide quality service to those with serious needs, ... this problem has recently presented itself, the new telemedicine platform and app, DocChat ...
Breaking Medicine News(10 mins):Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3
... Year End,2007 Earnings Webcast and Conference Call event:, ... 2007 Earnings Webcast and Conference Call March 31, ... Webcast and Conference Call event, please enter, http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2167880 ... conference call please dial into either,(604) 677-8677 or (800) ...
... announced today,that it has initiated coverage on leading Australian ... hand and royalty,revenue alone are equal to roughly US$0.94 ... DCF value for ART621 and you have a premium,of ... without assigning any,value to their current pre-clinical pipeline which ...
... Md., March 18 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... of,Directors has unanimously approved a three-for-two split of all ... share, including its Class,B Common Stock. Stockholders of record ... will receive one-half additional share of Common Stock for ...
... full Senate, moves to House, PHOENIX, March 18 ... Medicaid program to expend moneys to provide,smoking cessation treatments ... of 27 to 3., Currently, Arizona is one ... programs in the state,s Medicaid program, which in,Arizona is ...
... mental acuity may actually improve , , TUESDAY, March 18 ... treatment, head-and-neck cancer patients experience decreases in their physical ... quality of life, says a U.S. study. , ... that head and neck cancer treatment such as feeding ...
... -- For years, scientists have been proclaiming the benefits ... health have exploded in number, examining many health problems ... death. , Now, a University of Missouri researcher ... the Centers for Disease Control that a reduction in ...
Cached Medicine News:Health News:Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx) 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 3Health News:Arizona Senate Approves Smoking Cessation Treatments for State Medicaid Beneficiaries 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2Health News:Killer stairs? Taking the elevator could be worse for your body 2Health News:Killer stairs? Taking the elevator could be worse for your body 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: